Novartis Ag (NVS) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Novartis Ag  (NYSE: NVS)


Novartis Ag's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Novartis Ag's ROA in the fourth quarter of 2025?
Novartis Ag achieved a return on average assets (ROA) of 16.62 % in its fourth quarter of 2025, this is above NVS's average return on assets of 11.02%.
Novartis Ags assets during the 12 months ending in the fourth quarter of 2025 are valued at $108 billion

ROA has improved compared to 14.09% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 80 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 583.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change -15.55 % 8.51 % -19.66 % 6.31 % -0.12 %
Y / Y Net Income Change 16.99 % - 23.97 % - -19.62 %
Net Income (TTM) in million 17,991 15,963 15,963 15,185 15,185
Return On Assets (TTM) 16.62 % 14.09 % 14.36 % 12.92 % 13.1 %
NVS's Total Ranking # 583 # # # # 422
Total Assets (TTM) in million 110,949 110,949 104,395 106,580 131,379
Seq. Total Assets Change 0 % 6.28 % -2.05 % -18.88 % 28.49 %
Seq. Net Income Change - - - - -

NVS's 5 Years Annual ROA >> Back to NVS Management Effectiveness >> Compare NVS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 34
Sector # 81
Overall # 513

Return On Assets Statistics
High Average Low
18.22 %
11.02 %
5.92 %
(Dec 31 2021)   (Dec 31 2022)





Financial Statements
Novartis Ag's Assets $ 110,949 million NVS's Balance sheet
Novartis Ag's Income $ 13,967 million Quarterly NVS's Income Statement
NVS's Income by Division See NVS's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 7.59 % -0.12 % -26.67 % -3.75 % 4.34 %
Total Assets in million 141,354 131,379 131,538 179,368 186,350
Y / Y Net Income Change 16.99 % -19.62 % 113.57 % -71.04 % 197.58 %
Net Income in million 13,967 11,939 14,854 6,955 24,018
Annual Return On Assets 9.88 % 9.09 % 11.29 % 3.88 % 12.89 %

NVS's 5 Years Annual ROA >> Back to NVS Management Effectiveness >> Compare NVS ROA to its Competitors



Comment on NVS's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 9.88 % compared to prior year, due to annual net income growth of 16.99 % to $13,967.00 million, while value of Novartis Ag's overall assets grew just by 7.59 % to $141,354.00 million, compared to $141,354.00 a year before.


More Return On Assets Ratios
NVS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NVS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NVS's Competitors
Subscribers only: Roa for Novartis Ag's Suppliers
Subscribers only: Return On Assets for NVS's Customers

You may also want to know
NVS's Roi NVS's Inventory Turnover Ratio NVS's Growth Rates NVS's Dividend Comparisons
NVS's Profitability Ratios NVS's Asset Turnover Ratio NVS's Dividend Growth
NVS's Roe NVS's Valuation Ratios NVS's Financial Strength Ratios NVS's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Q32 Bio Inc   45.06 %
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %
Medinotec Inc   34.18 %
Zevra Therapeutics Inc   33.84 %
Oramed Pharmaceuticals Inc  33.67 %
Idexx Laboratories Inc  31.91 %
Acadia Pharmaceuticals Inc   29.77 %
Newgenivf Group Limited  29.73 %
Hutchmed china Limited  26.11 %
Petros Pharmaceuticals inc   26.04 %
Adma Biologics Inc   25.98 %
Theravance Biopharma inc   25.35 %
Ptc Therapeutics inc   25.21 %
Qhslab Inc   25.12 %
Medpace Holdings Inc   25.07 %
Mettler toledo International Inc   25.07 %
Compugen Ltd  22.57 %
Lifemd Inc   21.39 %
Catalyst Pharmaceuticals Inc   21.24 %
Iradimed Corporation  20.83 %
Incyte Corporation  20.70 %
Transmedics Group Inc   20.34 %
Eli Lilly And Company  19.76 %
Innoviva Inc   19.19 %

Date modified: 2026-09-08T15:11:38+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.